Objective: The aim of the study was to report on the presentation and outcomes of vesicular cystitis (VC), a chronic cystitis exhibiting translucent bladder mucosal vesicles, among women with antibiotic-refractory recurrent urinary tract infections (RUTIs). Methods: An analysis of our Institutional Review Board-approved series on antibiotic-refractory RUTIs was performed, selecting for documented VC lesions on cystoscopy. All patients had RUTIs defined as ≥3 urinary tract infections/year with positive urine culture. All patients were extensively treated with antibiotics with no resolution of RUTIs and were offered electrofulguration (EF) of VC lesions under anesthesia as a last resort. All patients had a 6-month post-EF office cystoscopy documenting persistence or resolution of the lesions, and a clinical outcome assessment based on RUTI frequency. Results: Of 482 patients, 18 (3.7%) treated during 2011–2017 met the study criteria. VC was most commonly found over the dome/anterior wall (7/18, 38%) and as pancystitis (7/18, 38%). There was often concomitant cystitis cystica of the trigone (8/18, 44%). At post-EF cystoscopy, persistence of VC was noted in 10/18 (56%) patients; 6/18 (33%) underwent repeat EF and an additional 3/18 (17%) were retreated due to new lesions after initial resolution. Two (11%) patients required simple cystectomy and urinary diversion due to RUTIs refractory to all interventions. Within a median follow-up of 2.8 years after EF, clinical cure was observed in 5/18 (28%), improvement in 10/18 (56%), and failure in 3/18 (17%) patients. Conclusions: Among women with antibiotic-refractory RUTIs, VC is an infrequent and persistent form of cystitis with a predilection for non-trigonal bladder surfaces, whose management is challenging.

1.
Schaeffer
AJ
,
Matulewicz
RS
,
Klumpp
DJ
.
Infections of the urinary tract
. In:
Wein
AJ
,
Kavoussi
LR
,
Partin
AW
,
Peters
CA
, editors.
Campbell-Walsh urology
.
Philadelphia, PA
:
Elsevier
;
2016
. Vol.
11
; p.
237
303
.
2.
Mysorekar
IU
,
Hultgren
SJ
.
Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract
.
Proc Natl Acad Sci U S A
.
2006
;
103
(
38
):
14170
5
.
3.
De Nisco
NJ
,
Neugent
M
,
Mull
J
,
Chen
L
,
Kuprasertkul
A
,
de Souza Santos
M
,
et al
.
Direct detection of tissue-resident bacteria and chronic inflammation in the bladder wall of postmenopausal women with recurrent urinary tract infection
.
J Mol Biol
.
2019
;
431
(
21
):
4368
79
.
4.
Hussain
SA
,
Alhalabi
F
,
Zimmern
PE
.
Long-term efficacy of fulguration of trigonitis for recurrent urinary tract infections in women
.
Urol Sci
.
2015
;
26
(
3
):
197
201
.
5.
Crivelli
JJ
,
Alhalabi
F
,
Zimmern
PE
.
Electrofulguration in the advanced management of antibiotic-refractory recurrent urinary tract infections in women
.
Int J Urol
.
2019
;
26
(
6
):
662
8
.
6.
Lee
CW
.
Epidermolysis bullosa acquisita associated with vesicular cystitis
.
Br J Dermatol
.
1988
;
119
(
1
):
101
5
.
7.
Malik
RD
,
Wu
YR
,
Zimmern
PE
.
Definition of recurrent urinary tract infections in women: Which one to adopt?
Female Pelvic Med Reconstr Surg
.
2018
;
113
:
26
33
.
8.
Zimmern
PE
,
De
EJ
.
Instrumentation for native tissue repair reconstructive procedures
. In:
Zimmern
PE
,
De
EJ
, editors.
Native tissue repair for incontinence and prolapse
.
Springer
;
2017
.
9.
Cifuentes
L
.
Epithelium of vaginal type in the female trigone; the clinical problem of trigonitis
.
J Urol
.
1947
;
57
(
6
):
1028
37
.
10.
Engel
G
,
Schaeffer
AJ
,
Grayhack
JT
,
Wendel
EF
.
The role of excretory urography and cystoscopy in the evaluation and management of women with recurrent urinary tract infection
.
J Urol
.
1980
;
123
(
2
):
190
1
.
11.
McClanahan
C
,
Grimes
MM
,
Callaghan
E
,
Stewart
J
.
Hemorrhagic cystitis associated with herpes simplex virus
.
J Urol
.
1994
;
151
(
1
):
152
3
.
12.
Rossanese
M
,
Palumbo
V
,
Sioletic
S
,
Crestani
A
,
Giannarini
G
,
Ficarra
V
.
Surgical treatment of eosinophilic cystitis in adults: a report of two cases and a literature review
.
Urol Int
.
2019
;
102
(
1
):
122
4
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.